Processa Pharmaceuticals (PCSA) Profit After Tax (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Profit After Tax came in at -$3.4 million in Q1 2026, down 19.15% YoY from -$4.2 million in Q1 2025, and up 0.53% on a QoQ basis from -$3.4 million in Q4 2025.
Processa Pharmaceuticals (PCSA) Profit After Tax (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Profit After Tax data on file, last reported at -$3.4 million in Q1 2026.
- Quarterly Profit After Tax fell 19.15% year-over-year to -$3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.1 million (down 18.27% YoY) and the FY2025 annual result came in at -$13.6 million, down 14.77% from the prior year.
- Profit After Tax improved to -$3.4 million in Q1 2026, from -$3.4 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$2.1 million in Q3 2023 to a low of -$13.0 million in Q4 2022.
- A 5-year average of -$4.0 million and a median of -$3.4 million in 2026 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax slumped 308.7% — and 2023, when it jumped 81.52%.
- Tracing PCSA's Profit After Tax over 5 years: stood at -$13.0 million in 2022, then jumped by 81.52% to -$2.4 million in 2023, then fell by 13.46% to -$2.7 million in 2024, then decreased by 24.42% to -$3.4 million in 2025, then rose by 0.53% to -$3.4 million in 2026.
- The last three Profit After Tax figures came in at -$3.4 million (Q1 2026), -$3.4 million (Q4 2025), and -$3.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - | -3.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.38 Mn |
| Dec 31, 2025 | -3.40 Mn |
| Sep 30, 2025 | -3.44 Mn |
| Jun 30, 2025 | -3.93 Mn |
| Mar 31, 2025 | -2.83 Mn |
| Dec 31, 2024 | -2.73 Mn |
| Sep 30, 2024 | -3.38 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Mar 31, 2024 | -2.73 Mn |
| Dec 31, 2023 | -2.40 Mn |
| Sep 30, 2023 | -2.08 Mn |
| Jun 30, 2023 | -2.61 Mn |
| Mar 31, 2023 | -4.02 Mn |
| Dec 31, 2022 | -13.01 Mn |
| Sep 30, 2022 | -6.02 Mn |
| Jun 30, 2022 | -5.16 Mn |
| Mar 31, 2022 | -3.23 Mn |
| Dec 31, 2021 | -3.18 Mn |
| Sep 30, 2021 | -2.99 Mn |
| Jun 30, 2021 | -3.16 Mn |